Treprostinil

Treprostinil
(IUPAC) ime
	(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-heksahidro-2-hidroksi-; 1-[(3S)-3-hidroksioktil]-1H-benz[f]inden-5-il]; oksi]sirćetna kiselina
Klinički podaci
Robne marke	Remodulin, Tyvaso
AHFS/Drugs.com	Mikromedeks, detaljne potrošačke informacije
MedlinePlus	a600042
Identifikatori
CAS broj	289480-64-4
ATC kod	B01AC21
PubChem	6918140
DrugBank	DB00374
ChemSpider	5293353
UNII	RUM6K67ESG
ChEBI	CHEBI:50861
ChEMBL	CHEMBL1201254
Hemijski podaci
Formula	C23H34O5
Mol. masa	390,52 g/mol
InChI
	InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1 ; Key: PAJMKGZZBBTTOY-ZFORQUDYSA-N
Farmakokinetički podaci
Bioraspoloživost	aproksimativno 100%
Metabolizam	Treprostinil je u znatnoj meri metabolisan u jetri
Poluvreme eliminacije	4 sata
Izlučivanje	Urin (79); fekalije (13%)
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Supkutano ili intravenozno, inhalacija

Treprostinil (Remodulin, Tivaso) je sintetički analog prostaciklina (PGI₂).

Klinička farmakologija[uredi | uredi kod]

Glavni efekat treprostinila je vazodilatacija arterija u plućima. Treprostinil takođe inhibira agregaciju trombocita.

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

Remodulin Full Prescribing Information US Patent No. 5,153,222
UT_OpinVEvid_FEB09v.1
Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy nonresponders for the treatment of pulmonary arterial hypertension L. Narine, L. K. Hague, J. H. Walker, C. Vicente, R. Schilz, O. Desjardins, T. R. Einarson and M. Iskedjian

	Portal Medicina
	Portal Hemija